ASH-FDA Joint Symposium on New Drug Approvals in Acute Myeloid Leukemia


This joint session, co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat acute myeloid leukemia (AML). FDA product-reviewers will discuss the safety and efficacy issues from the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time at the end of the session for audience questions.


  • Aviva C. Krauss
  • Laura C. Michaelis
  • Kelly Norsworthy
  • Ashley F. Ward


Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top